Overview

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID in Healthy Adult Volunteers

Status:
Not yet recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

This is Phase 1 and 2a, Multi-center, Open-label study designed to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID vaccine in Healthy Adult Volunteers

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

EyeGene Inc.

Collaborator:

Novotech (Australia) Pty Limited